ArticleStatistics in medicine2026
Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.
Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
When multiple vaccines are simultaneously recommended, a statistical method to monitor adverse events accounting for multiple combinations of vaccine exposure rather than each vaccine individually is preferred. We introduce an adaptive multiple hypotheses test method for rapidly detecting increased risks of adverse events from one or more combinations of simultaneous vaccine exposure, for example, exposed to influenza vaccination only; exposed to COVID and influenza vaccinations; exposed to COVID, influenza, and respiratory syncytial virus (RSV) vaccinations. We do this by extending the binomial maximized sequential probability ratio test (MaxSPRT) method to a multinomial probability model. With an exact analytical alpha spending approach, the computationally feasible limit of multiple exposures is likely limited to two vaccines. For more complex situations with three or more vaccines and multiple adverse event endpoints, we demonstrate a valid Monte Carlo approach. Illustrative examples and simulation studies were performed with the R Sequential package.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.